First‑in‑class METTL3 inhibitor reprograms malignant progenitor cells by modulating mRNA methylation
CAMBRIDGE, United Kingdom, April 16, 2026 (GLOBE NEWSWIRE) -- STORM Therapeutics Ltd. (STORM), the clinical stage company targeting RNA modifications to reprogram cells and develop novel cancer therapies, today announced a successful $56 million Series C financing.
The proceeds will support the advancement of STC-15, a first‑in‑class, oral small-molecule inhibitor of METTL3, including funding the Company's Phase 2 monotherapy study in selected sarcoma indications, in which the first patient has now been successfully dosed. Sarcoma is a form of cancer that arises in bone or soft tissues, including muscle, fat, cartilage, blood vessels, and other connective or supportive tissue. This study is designed to support a potential accelerated regulatory approval pathway for STC-15 and to establish a foundation for subsequent clinical development across additional oncology indications.
STC-15 inhibits METTL3, an RNA-modifying enzyme involved in the regulation of cancer stem cell differentiation, a critical process in the development of sarcomas and other malignancies. In a Phase 1 monotherapy study, STC-15 demonstrated durable tumor regression across multiple sarcoma subtypes, underscoring its potential to target and reprogram progenitor cells ...
